Drug Profile
Research programme: autoimmune therapies - Biodexa Pharmaceuticals/Cardiff University
Latest Information Update: 16 May 2023
Price :
$50
*
At a glance
- Originator Cardiff University; Midatech
- Developer Biodexa Pharmaceuticals; Cardiff University
- Class Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 1 diabetes mellitus